AZN
The numbers still look pretty beefy
AstraZeneca's FY 2025 results weren't exactly a disaster movie. Gross margin came in at 80%, down 2 points, thanks to profit-sharing on drugs like Lynparza and Enhertu, a $235 million royalty buyout for Saphnelo and rilvegostomig, plus some US pricing adjustments.
The margin nitpick
If you're squinting at the report, the headline is simple: the company is still making plenty of money, but the economics of doing business are getting a little more complicated. Profit-sharing and royalty buyouts are the corporate version of splitting the dinner check three ways — nobody loves it, but sometimes it's the price of being at the table.
Operating profit says the machine is still running
The more important bit for investors: reported operating profit rose 37% to $13.7 billion, while core operating profit climbed 9% to $18.5 billion. That suggests the underlying business is still growing, even after accounting for amortization and impairments that can make the GAAP view look messier than the adjusted one.
Why you should care
For a big pharma name like AstraZeneca, the market usually cares less about one line item and more about the trend: can the portfolio keep growing, and can management protect profitability while it does it? This report says yes, with a small asterisk next to margin pressure.
Big picture: the story here is not "uh-oh," it's "growth is alive, but the bill for staying competitive is getting a little bigger."